Multiple Gastric Cancer Tissue Proteomic Identification Predicts CLU as a Biomarker for Anti-PD-1 Immunotherapy
Date
Authors
Zhang, Yu
Zhu, Hao-Yi
Ma, Cong-Cong
Wang, Ning
Li, Yan
Lu, Guo-Liang
Dai, Xing-Jie
Wang, Bo
Mamun, MAA
Li, Ying
Supervisor
Item type
Journal Article
Degree name
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
Abstract
Highlights • Clusterin (CLU) is a new negative predictive biomarker for anti-PD-1 immunotherapy of gastric cancer (GC). • CLU is a pivotal regulator of both tumor-intrinsic proliferation and immune evasion in GC. • CLU abrogation in GC enhances the immune response, boosting T-cell killing ability activity and cytokine secretion.Description
Keywords
32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, 3204 Immunology, Biotechnology, Rare Diseases, Digestive Diseases, Precision Medicine, Cancer, Stomach Cancer, Immunization, Immunotherapy, Vaccine Related, 5.1 Pharmaceuticals, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Cancer
Source
Journal of Pharmaceutical Analysis, ISSN: 2095-1779 (Print), Elsevier BV, 101615-101615. doi: 10.1016/j.jpha.2026.101615